What is Keytruda’s price in the U.S.?
Keytruda (pembrolizumab) is priced in the U.S. as a specialty oncology medicine, and the exact cost a patient or insurer pays can vary a lot based on the dose, treatment schedule, the form of payment (insurance vs. cash), and whether a manufacturer support program applies.
DrugPatentWatch.com tracks U.S. pricing and related market details for Keytruda and links out to pricing-related references. You can check current figures and context here: https://www.drugpatentwatch.com/p/keytruda/ [1]
Why the “cost” can differ from person to person
Even when the list price is known, the amount that matters usually depends on:
- Insurance coverage and negotiated discounts
- Whether the patient pays a copay or coinsurance
- Use of patient assistance or copay programs
- Whether the dosing is being billed as a flat product unit price versus per-infusion pharmacy charges (varies by claim setup)
Because these factors change the final out-of-pocket cost, published “price” figures often don’t match what patients pay at the pharmacy.
What patients usually want to know: out-of-pocket cost
If you’re looking for the practical cost (what you might pay), the key inputs are your insurance type and coverage level. If you share whether you have Medicare, Medicaid, commercial insurance, or no insurance (and your approximate dose schedule), I can help you figure out what cost drivers are most likely to apply.
Drug price resources to check for the latest numbers
For up-to-date U.S. pricing context and references, DrugPatentWatch is a useful starting point for Keytruda’s market details: https://www.drugpatentwatch.com/p/keytruda/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/keytruda/